First Wave BioPharma, Inc. (FWBI) PT Lowered to $18 at Roth Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts FWBI Hot Sheet
Price: $2.96 --0%
Rating Summary:
0 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
0 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Roth Capital analyst Jonathan Aschoff lowered the price target on First Wave BioPharma, Inc. (NASDAQ: FWBI) to $18.00 (from $25.00) while maintaining a Buy rating.
You May Also Be Interested In
- Flutter Entertainment (FLUT) PT Lowered to $160 at Jefferies
- Sportradar Group AG (SRAD) PT Raised to $16 at StoneX
- Bruker (BRKR) PT Raised to $70 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
